Skip to main content

Table 3 Acute toxicity during and 3 months after EBRT followed by MRg-SBRT boost, according to Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0

From: MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience

Toxicity

Acute

≥ 3 months after SBRT

Grade I

Grade II

Grade ≥ III

Grade I

Grade II

Grade ≥ III

Diarrhea

3

  

1

  

Proctitis

2

  

1

  

Pollakisuria

2

  

1

  

Dysuria

5

1

 

3

  

Nycturia

5

  

4

  

Urinary urgency

4

  

3

  

Urinary incontinence

 

1

 

1

  

Vaginal discharge

4

  

2

  

Dermatitis

1

1

 

1

  
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us